Resona Asset Management Co. Ltd. Sells 3,795 Shares of Stryker Corporation $SYK

Resona Asset Management Co. Ltd. reduced its stake in shares of Stryker Corporation (NYSE:SYK) by 3.6% in the fourth quarter, HoldingsChannel.com reports. The fund owned 102,593 shares of the medical technology company’s stock after selling 3,795 shares during the quarter. Resona Asset Management Co. Ltd.’s holdings in Stryker were worth $36,077,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in SYK. AMF Tjanstepension AB lifted its stake in Stryker by 7.8% in the fourth quarter. AMF Tjanstepension AB now owns 187,059 shares of the medical technology company’s stock worth $65,746,000 after purchasing an additional 13,524 shares during the last quarter. Profund Advisors LLC lifted its stake in Stryker by 24.2% in the fourth quarter. Profund Advisors LLC now owns 5,766 shares of the medical technology company’s stock worth $2,027,000 after purchasing an additional 1,122 shares during the last quarter. ProShare Advisors LLC lifted its stake in Stryker by 8.4% in the fourth quarter. ProShare Advisors LLC now owns 65,383 shares of the medical technology company’s stock worth $22,980,000 after purchasing an additional 5,047 shares during the last quarter. Wolff Financial Management LLC lifted its stake in Stryker by 1.4% in the fourth quarter. Wolff Financial Management LLC now owns 9,266 shares of the medical technology company’s stock worth $3,257,000 after purchasing an additional 125 shares during the last quarter. Finally, WD Rutherford LLC lifted its stake in Stryker by 0.5% in the fourth quarter. WD Rutherford LLC now owns 10,660 shares of the medical technology company’s stock worth $3,747,000 after purchasing an additional 50 shares during the last quarter. 77.09% of the stock is owned by institutional investors.

Insider Activity

In other Stryker news, VP M Kathryn Fink sold 5,220 shares of the business’s stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $283.85, for a total value of $1,481,697.00. Following the transaction, the vice president owned 13,137 shares in the company, valued at approximately $3,728,937.45. The trade was a 28.44% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 4.60% of the company’s stock.

Stryker Price Performance

SYK stock opened at $312.99 on Tuesday. The firm’s 50-day moving average price is $328.54 and its two-hundred day moving average price is $351.06. Stryker Corporation has a 12-month low of $281.00 and a 12-month high of $404.87. The stock has a market capitalization of $119.99 billion, a price-to-earnings ratio of 36.23, a PEG ratio of 1.93 and a beta of 0.80. The company has a current ratio of 2.11, a quick ratio of 1.25 and a debt-to-equity ratio of 0.62.

Stryker (NYSE:SYK) last released its quarterly earnings data on Thursday, April 30th. The medical technology company reported $2.60 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). Stryker had a net margin of 13.20% and a return on equity of 23.42%. The firm had revenue of $6.02 billion during the quarter, compared to analysts’ expectations of $6.34 billion. During the same quarter in the previous year, the firm posted $2.84 EPS. Stryker’s revenue was up 2.6% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. As a group, equities analysts predict that Stryker Corporation will post 14.98 earnings per share for the current year.

Stryker Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th will be given a $0.88 dividend. The ex-dividend date is Tuesday, June 30th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. Stryker’s payout ratio is presently 40.74%.

Analysts Set New Price Targets

SYK has been the subject of several recent research reports. The Goldman Sachs Group reissued a “neutral” rating and issued a $361.00 price target on shares of Stryker in a research note on Friday, May 1st. Truist Financial reissued a “hold” rating and issued a $330.00 price target (down from $380.00) on shares of Stryker in a research note on Monday, May 4th. Evercore set a $355.00 price target on shares of Stryker in a research note on Friday, May 1st. UBS Group lowered their price target on shares of Stryker from $400.00 to $380.00 and set a “neutral” rating for the company in a research note on Tuesday, March 17th. Finally, Barclays lowered their price target on shares of Stryker from $469.00 to $394.00 and set an “overweight” rating for the company in a research note on Monday, May 4th. Sixteen investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat, Stryker currently has an average rating of “Moderate Buy” and an average price target of $395.48.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.